With the purpose of exploring this possibility, we performed an in silico study [16], showing the differential capability of S100B to interact with the proteome of a healthy and IBD microbiota, suggesting a possible role at the mucosa–microbiota barrier, in the ENS, and in the gut microbiota axis. Here, S100B is linked to inflammatory bowel disease.